Elemental analysis by Metallobalance provides a complementary support layer over existing blood biochemistry panel-based cancer risk assessment

PeerJ

article

Miho Kusakabe¹  Masahiro Sato²  Yohko Nakamura²  Haruo Mikami²  Jason Lin³  Hiroki Nagase¹ 

[1] Graduate School of Medical and Pharmaceutical Sciences, Chiba University;Cancer Prevention Center, Chiba Cancer Center Research Institute;Division of Clinical Genomics, Chiba Cancer Center Research Institute;Division of Cancer Genetics, Chiba Cancer Center Research Institute

关键词: Cancer biology;    Chemical biology;    Epidemiology;    Mass spectrometry;    Preventative medicine;   

DOI  :  10.7717/peerj.12247

学科分类：社会科学、人文和艺术（综合）

来源: Inra

【 摘 要 】

Despite the benefit of early cancer screening, Japan has one of the lowest cancer screening rates among developed countries, possibly due to there being a lack of “a good test” that can provide sufficient levels of test sensitivity and accuracy without a large price tag. As a number of essential and trace elements have been intimately connected to the oncogenesis of cancer, Metallobalance, a recent development in elemental analysis utilizing the technique of inductively coupled plasma mass spectrometry has been developed and tested as a robust method for arrayed cancer risk screening. We have conducted case-control epidemiological studies in the prefecture of Chiba, in the Greater Tokyo Area, and sought to determine both Metallobalance screening’s effectiveness for predicting pan-cancer outcomes, and whether the method is capable enough to replace the more conventional antigen-based testing methods. Results suggest that MB screening provides some means of classification potential among cancer and non-cancer cases, and may work well as a complementary method to traditional antigen-based tumor marker testing, even in situations where tumor markers alone cannot discernibly identify cancer from non-cancer cases.

【 授权许可】

CC BY